GeoVax Labs, Inc. (GOVX) Fair Value 2026

GOVX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.7 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (42/100)

Quick Summary — As of 2026-10-07, GeoVax Labs, Inc. (GOVX) trades at $0.29. QOC: 5.7/10. Value Trap Risk: 42/100 (WARN). 1/13 models active.

Key Facts

Ticker
GOVX
Price
$0.29
Quality Score
5.7/10
Value Trap Risk
42/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +42.1% upside with 28% confidence
Risk: Value Trap score of 42 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give GOVX?

1 Intrinsic Value Models vs. Current Price ($0.29)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $0.41 +42.1%

All Models Active

All 1 models are displayed above.

What Is GeoVax Labs, Inc. (GOVX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for GeoVax Labs, Inc.. Trading at $0.29 against an estimated intrinsic value of $0.41, 1 of 1 active models flag meaningful upside of +42.1% at the median.

What Do the Models Say About GOVX?

1 of 13 models are currently active for GOVX. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does GOVX Rank in Biotechnology?

Among 622 Biotechnology stocks, GOVX ranks #183 by Quality of Company score. CirclFi's QOC score of 5.7/10 evaluates 32 fundamental signals. A score of 5.7 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotech businesses. For GeoVax Labs, Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is GOVX a Value Trap?

CirclFi's Value Trap algorithm assigns GOVX a score of 42/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for GeoVax Labs, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, GeoVax Labs, Inc. scores 5.7 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every GOVX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across GOVX's 1 active models, average confidence is 28%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy GeoVax Labs, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

OVIDOvid Therapeutics Inc.QOC 5.7WHWKWhitehawk Therapeutics, Inc.QOC 5.7OABIOmniAb, Inc.QOC 5.7MGXMetagenomi Therapeutics, Inc.QOC 5.7SXTP60 Degrees Pharmaceuticals, Inc.QOC 5.8TRDAEntrada Therapeutics, Inc.QOC 5.7SLDBSolid Biosciences Inc.QOC 4.9GUTSFractyl Health, Inc.QOC 4.2TGTXTG Therapeutics, Inc.QOC 8.1EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: OVID · WHWK · OABI · MGX · SXTP · TRDA · SLDB · GUTS · TGTX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to GOVX?

6 companies across all industries closest to GOVX’s Quality of Company score of 5.7/10.

FCHLFitness Champs Holdings LimitedQOC 5.7BKDBrookdale Senior Living Inc.QOC 5.7MEGLMagic Empire Global LimitedQOC 5.7CIITTianci International, Inc.QOC 5.7LQMTLiquidmetal Technologies, Inc.QOC 5.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: FCHL · BKD · MEGL · CIIT · LQMT · NVDA

Where Does GOVX Sit in CirclFi's Biotechnology Rankings?

GOVX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About GeoVax Labs, Inc.’s Valuation?

What is GeoVax Labs, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for GeoVax Labs, Inc. (GOVX). The Quality of Company score is 5.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is GOVX overvalued or undervalued right now?

At $0.29, 1 of 1 active models suggest GOVX may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits GeoVax Labs, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.7 mean for GOVX?

GeoVax Labs, Inc.'s QOC of 5.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on GOVX?

CirclFi analyzes GOVX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is GOVX a value trap in 2026?

GeoVax Labs, Inc.'s Value Trap score is 42/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns GeoVax Labs, Inc. (GOVX) a Quality of Company score of 5.7/10 across 32 fundamental signals as of 2026-10-07.” Source: circlfi.com/stock/GOVX/ · Methodology
Primary sources for this GOVX valuation
  • Financial statements: GeoVax Labs, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000832489) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for GOVX as of ; valuations recomputed .